Abstract
Nine patients with chronic posterior endogenous uveitis of varying aetiology, not satisfactorily controlled with systemic corticosteroids alone, were treated with low dose oral Cyclosporin A (mean maintenance dose 4.0 ±1.1 mg/kg/day). Six of the nine patients also continued to receive oral prednisolone (15 mg/day or less). During a follow up period of 6-30 (mean 17) months, seven have shown sustained visual improvement. Nephrotoxicity was the major side effect with serum creatinine concentration (mean ± 1SD) rising from 91±7 μmol/1 to 115±13 μmol/1 (0.01<p<0.05) after the first twelve months of treatment. Other observed side effects have included taste disturbance, hypomagnesaemia, and hypertension.
Cyclosporin A treatment is of value in the management of severe intraocular inflammation, unresponsive to conventional therapy, but the optimum duration of therapy remains to be established and nephrotoxicity is the major dose limiting effect.
Similar content being viewed by others
Article PDF
References
Department of Health and Social Security: Blindness and partial sight in England 1969-1976. London: HMSO. 1979. (Reports on Public Health and Medical Subjects No. 129).
Nussenblatt RB . Palestine AG . Rook AH et al.: Treatment of intraocular inflammatory disease with Cyclosporin A. Lancet 1983, ii: 235–38.
Nussenblatt RB, Palestine AG, Chan CC : Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteriods and cytotoxic agents. Am J Ophthalmol 1983, 96: 275–82.
Nussenblatt RB, Rodrigues MM, Wacker WB . et al.: Cyclosporin A: Inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest 1981, 67: 1228–31.
Striph G, Doft B, Rabin B, Johnson B : Retinal S antigen induced uveitis: the efficacy of cyclosporine and corticosteroids in treatment. Arch Ophthalmol 1986, 104: 114–17.
Stanford MR, Atkinson E, Kasp E, Dumonde DC : Modulation of experimental retinal vasculitis using dexamethasone, cyclosporin A, and prazosin. Eye 1987, 1: 626–31.
Hill JC and Potter P : Treatment of Mooren's ulcer with cyclosporin A: report of three cases. Br J Ophthalmol 1987, 71: 11–15.
Müftüoğlu AÜ, Pazarli H, Yurdakul S . et al.: Short term cyclosporin A treatment of Belief's disease. Br J Ophthalmol 1987, 71: 387–90.
Binder AI, Graham EM, Sanders MD, Dinning W, James DG, Denman AM : Cyclosporin A in the treatment of severe Beliefs uveitis. Br J Rheu-matol 1987, 26: 285–91.
Weetman AP, McGregor AM, Ludgate M . et al.: Cyclosporin A improves Graves' ophthalmopathy. Lancet 1983, ii: 486–9.
Kahaly G, Schrezenmeir J, Krause U . et al.: Cyclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomised and prospective study. Eur J Clin Invest 1986, 16: 415–22.
Utech C, Wulle KG, Bieler EU . et al.: Treatment of severe Graves' ophthalmopathy with cyclosporin A. Acta Endocr 1985, 110: 493–8.
Coster DJ, Shepherd WF, Chin Fook T . et al.: Prolonged survival of corneal allografts in rabbits treated with cyclosporin A. Lancet 1979, ii: 688–9.
Bell TAG, Easty DL, McCullagh : placebo-controlled blind trial of cyclosporin A in prevention of corneal graft rejection in rabbits. Br J Ophthalmol 1982, 66: 303–8.
Bennett WM and Norman OJ : Action and toxicity of cyclosporine. Ann Rev Med 1986, 37: 215–24.
Palestine AG, Nussenblatt RB, Chan CC : Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med 1984, 77: 652–6.
Bending JJ, Ogg CS, Viberti GC : Diabetogenic effect of cyclosporin. Br Med J 1987, 294: 401–2.
Dumonde DC, Kasp-Grochowska E, Graham EM, Sanders MD, Faure JP, de Kozak Y : and van Tuyen V . Anti-retinal autoimmunity and circulating immune complexes in patients with retinal vasculitis. Lancet 1982, ii: 787–92.
Hogan MJ, Kimura SJ and Thygeson P : Signs and symptoms of uveitis. I. anterior uveitis. Am J Ophthalmol 1959, 47 (Suppl.): 155–70.
Kimura SJ, Thygeson P, Hogan MJ : Signs and symptoms of uveitis. II. Classification of the posterior manifestations of uveitis. Am J Ophthalmol 1959, 47 (Suppl.): 171–6.
Nussenblatt RB, Palestine AG, Chan CC, Roberge F : Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985, 92: 467–71.
Palestine AG, Austin HA, Balow JE . et al.: Renal histopathological alterations in patients treated with cyclosporine for uveitis. N Eng J Med 1986, 314: 1293–8.
Svenson K, Bohman SO, Hallgren R : Renal interstitial fibrosis and vascular changes. Occurrence in patients with autoimmune diseases treated with Cyclosporine. Arch Int Med 1986, 146: 2007–10.
Klintmalm, G, Bohman S, Sundclin B, Wilczek H : Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplantation period. Lancet 1984, ii: 950–4.
Rebuck AS, Sanders BR, MacFadden OK . et al.: Cyclosporin in pulmonary sarcoidosis. Lancet 1987, i: 1486.
Author information
Authors and Affiliations
Additional information
Presented at the Scottish Ophthalmological Club and Norwegian Ophthalmological Society Combined Meeting, October 1987, Aberdeen.
Rights and permissions
About this article
Cite this article
Towler, H., Cliffe, A., Whiting, P. et al. Low dose cyclosporin a therapy in chronic posterior uveitis. Eye 3, 282–287 (1989). https://doi.org/10.1038/eye.1989.39
Issue Date:
DOI: https://doi.org/10.1038/eye.1989.39
This article is cited by
-
Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis
Eye (2009)
-
Immunomodulation of experimental autoimmune uveoretinitis: A model of tolerance induction with retinal antigens
Eye (1994)
-
The efficacy of systemic corticosteroids in sight-threatening retinal vasculitis
Eye (1994)
-
Macular ischaemia in posterior uveitis
Eye (1993)
-
Immunocytochemical analysis of blood lymphocytes in uveitis
Eye (1992)